EFFECT OF IVABRADINE COMBINED WITH METOPROLOL ON SERUM GAL-3, CTNI LEVELS, AND CARDIAC STRUCTURE AND FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE

Objective: To explore the effect of ivabradine combined with metoprolol on serum Gal-3 and cTnI levels and cardiac structure and function in patients with chronic heart failure (CHF). Methods: 142 CHF patients at our hospital from February 2020 to March 2021 were randomly divided into an observation group (n = 71) and a control group (n = 71). The control group was treated with metoprolol sustained-release tablets, and the observation group was treated with ivabradine on the basis of the control group. The effective rate, the incidence of adverse reactions, the levels of Gal-3, cTnI, and B-type brain natriuretic peptide (BNP), and the improvement of NYHA cardiac function were compared between the two groups before and after treatment. Results: Compared with the total effective rate of 76.06% (54/71) in the control group, the total effective rate of 91.55% (65/71) in the observation group represented a significant increase (P<0.05). Compared with levels prior to treatment, the levels of Gal-3, cTnI, and BNP in the two groups were significantly decreased following treatment (P<0.05); compared with the control group, the levels of Gal-3, cTnI, and BNP in the observation group were significantly decreased (P<0.05). Compared with conditions prior to treatment, LVESD and LVEDd in the two groups were significantly decreased, while LVEF was significantly increased (P<0.05); compared with the control group following treatment, LVESD and LVEDd in the observation group were significantly decreased, while LVEF was significantly increased (P<0.05). Compared with grades prior to treatment, the cardiac function grades of the two groups were significantly improved after treatment (P<0.05); following treatment, the improvement of cardiac function classification in the observation group was more significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group: 8.45% (6/71) vs 7.04% (5/71) (P>0.05). Conclusion: The effect of ivabradine combined with metoprolol in the treatment of CHF patients is ideal-the combination can significantly improve their cardiac function and reduce the levels of Gal-3, cTnI, and BNP in serum, with high safety and reliability.